Literature DB >> 25031517

Prevalence of thrombophilia in asymptomatic individuals with a family history of thrombosis.

E Vagdatli1, O Serafimidou1, E Pantziarela1, F Tsikopoulou1, K Mitsopoulou1, A Papoutsi1.   

Abstract

OBJECTIVE: The present study investigates the prevalence of thrombophilia in individuals with first or/and second degree family history of thromboembolism. MATERIAL-
METHODS: The study group consisted of 68 individuals with a first or second degree family history of venous or arterial thromboembolism, but without a personal history of thrombosis. The activity of ATIII, PC, PS, FVIII, FΧΙΙ and total homocysteine was measured on the ACL Advance coagulation analyzer. In addition, hemi-quantitative determination of CRP was performed to exclude an acute phase reaction. The existence of V-Leiden mutation was investigated by the modified pre-dilution method (1:5) with V-DEF. Prothrombin G20210A mutation was detected by the use of an in house PCR protocol. Family history was termed as follows: positive (thrombosis was reported in one parent and his/her family members) (group Α) or strongly positive (thrombosis was reported in both parents and their family members (group Β).
RESULTS: Data analysis revealed decreased activity of ATIII:1.47%, PC:1.47%, and FXII:5.9%, increased activity of FVIII (without inflammation):11.8%, V-Leiden:13%, elevated Hcy:14.7%, and G20210A mutation:2.9%. Group A consisted of 55 individuals (74.5%), whereas group B of 16 (23.5%). The total percentage of thrombophilia was 48.5%, while the percentage within group A was 44.2% and within group B 62.5%.
CONCLUSION: The high prevalence of thrombophilia, reinforce the importance of an extensive laboratory thrombophilia screening when a family history of thromboembolism has been recorded, especially when it concerns both parents and/or their family members and even more when one or more acquired thrombophilic factors coexist.

Entities:  

Keywords:  APC resistance; Familial thrombosis; coagulation factors; coagulation inhibitors; hypercoagulability

Year:  2013        PMID: 25031517      PMCID: PMC4097419     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  18 in total

1.  Efficacy of family history in determining thrombophilia risk.

Authors:  Jennifer E Dietrich; S Paige Hertweck; Sally E Perlman
Journal:  J Pediatr Adolesc Gynecol       Date:  2007-08       Impact factor: 1.814

2.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.

Authors:  S R Poort; F R Rosendaal; P H Reitsma; R M Bertina
Journal:  Blood       Date:  1996-11-15       Impact factor: 22.113

3.  Psychological impact of thrombophilia testing in asymptomatic family members.

Authors:  Martha L Louzada; Monica Taljaard; Nicole J Langlois; Susan R Kahn; Marc A Rodger; David R Anderson; Michael J Kovacs; Philip S Wells
Journal:  Thromb Res       Date:  2011-07-06       Impact factor: 3.944

4.  Family history and inherited thrombophilia.

Authors:  G L van Sluis; M Söhne; D Y El Kheir; M W Tanck; V E A Gerdes; H R Büller
Journal:  J Thromb Haemost       Date:  2006-10       Impact factor: 5.824

Review 5.  Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders.

Authors:  Richard D Press; Kenneth A Bauer; Jody L Kujovich; John A Heit
Journal:  Arch Pathol Lab Med       Date:  2002-11       Impact factor: 5.534

6.  Thrombophilia testing in patients with venous thrombosis.

Authors:  J A Caprini; S Goldshteyn; C J Glase; K Hathaway
Journal:  Eur J Vasc Endovasc Surg       Date:  2005-08-01       Impact factor: 7.069

Review 7.  Factor V Leiden: should we screen oral contraceptive users and pregnant women?

Authors:  J P Vandenbroucke; F J van der Meer; F M Helmerhorst; F R Rosendaal
Journal:  BMJ       Date:  1996-11-02

Review 8.  Management of thrombophilia: who to screen?

Authors:  Trevor Baglin
Journal:  Pathophysiol Haemost Thromb       Date:  2003 Sep-2004 Dec

9.  The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: evaluation of the incidence of FXII deficiency among 300 healthy blood donors.

Authors:  W M Halbmayer; A Haushofer; R Schön; C Mannhalter; E Strohmer; K Baumgarten; M Fischer
Journal:  Thromb Haemost       Date:  1994-01       Impact factor: 5.249

Review 10.  The psychological impact of testing for thrombophilia: a systematic review.

Authors:  D M Cohn; F Vansenne; A A Kaptein; C A J M De Borgie; S Middeldorp
Journal:  J Thromb Haemost       Date:  2008-07-01       Impact factor: 5.824

View more
  1 in total

1.  Prevalence and Multiplicity of Thrombophilia Genetic Polymorphisms of F V, MTHFR, F II, and PAI -I: A Cross-Sectional Study on a Healthy Jordanian Population.

Authors:  Nabil Al-Zoubi; Nasr Alrabadi; Khalid Kheirallah; Ahmad Alqudah
Journal:  Int J Gen Med       Date:  2021-09-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.